PUBLICATIONS



  1. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study: Diabetes Obes Metab. - 2022
  2. Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes: Pharmacoepidemiol Drug Saf. - 2022​
  3. Prevalence of Avoidable and Bias-Inflicting Methodological Pitfalls in Real-World Studies of Medication Safety and Effectiveness: Clin Pharmacol Ther. -2022
  4. Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes: Clin Gastroenterol Hepatol. - 2022
  5. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes: Am J Kidney Dis. - 2022
  6. Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data: Pharmacoepidemiol Drug Saf. - 2022
  7. Risk of Hospitalization for Heart Failure in Patients With Hyperkalemia Treated With Sodium Zirconium Cyclosilicate Versus Patiromer: J Card Fail. - 2022
  8. Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries: Diabetes Care. - 2022
  9. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study: Ann Intern Med. - 2022
  10. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes: Am J Kidney Dis. - 2022
  11. Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes: Pharmacoepidemiol Drug Saf. - 2022
  12. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes: JAMA Netw Open - 2021
  13. Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study: Diabetes Care. - 2021
  14. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease: Ann Intern Med. - 2021
  15. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults: Diabetes Care. - 2021
  16. Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments: Endocr Rev. - 2021
  17. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy:  Circulation. -2021 
  18. Validation of obesity-related diagnosis codes in claims data: Diabetes Obes Metab.​ - 2021
  19. The modifying effects of adiposity on the cardiovascular safety of sulphonylureas: Diabetes Obes Metab. - 2021
  20. Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States: Diabetes Obes Metab.​ - 2021
  21. How well can we assess the validity of non-randomised studies of medications? A systematic review of assessment tools: BMJ Open. - 2021
  22. Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA: Diabetes Care. - 2021
  23. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy: Circulation. - 2021
  24. A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes: Endocrinol Diabetes Metab.​ - 2021
  25. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease: Ann Intern Med.​ - 2021
  26. Comparative effectiveness of empagliflozin in reducing total cardiovascular events in the empagliflozin comparative effectiveness and safety (EMPRISE) study: Journal of the American College of Cardiology - 2021
  27. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease: Clin J Am Soc Nephrol​ -2020
  28. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study: Ann Intern Med. - 2020
  29. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018: Diabetes Care. - 2020
  30. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis: Cardiovascular Diabetology. - 2020
  31. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea: JAMA Dermatol. - 2020
  32. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study: BMJ. - 2020
  33. Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications: Value Health. - 2020
  34. Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes: Diabetes Obes Metab. - 2020
  35. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care: Endocrinol Diabetes Metab. - 2019
  36. Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data: Diabetes Obes Metab. - 2019
  37. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study: Ann Intern Med. - 2019
  38. Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care: Diabetes Obes Metab. - 2019
  39. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: Circulation.​ - 2019
  40. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study: Ann Intern Med. - 2019
  41. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors: Diabetes Obes Metab. 2019
  42. Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome: Pharmacoepidemiol Drug Saf. - 2018
  43. Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records: Diabetes Obes Metab. - 2018
  44. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study: BMJ. - 2018

​
Division of Pharmacoepidemiology & Pharmacoeconomics
Department of Medicine
Brigham & Women's Hospital and Harvard Medical School
1620 Tremont Street Suite 3030 Boston, MA 02120
Proudly powered by Weebly